Adverse event—serious 16 to 60 weeks · people with asthma
Subcutaneous omalizumab + steroid probably leads to lower adverse event—serious 16 to 60 weeks compared with placebo + steroid (stable steroid) (moderate certainty).
1 finding from 1 review
Number of participants achieving complete inhaled steroid withdrawal 28 to 32 weeks · people with asthma
Subcutaneous omalizumab + steroid may leads to higher number of participants achieving complete inhaled steroid withdrawal… compared with placebo + steroid (steroid reduction) (low certainty).
1 finding from 1 review
>50% reduction in inhaled steroid usage 28 to 32 weeks · people with asthma
Subcutaneous omalizumab + steroid probably leads to higher >50% reduction in inhaled steroid usage 28 to 32 weeks compared with placebo + steroid (steroid reduction) (moderate certainty).
1 finding from 1 review
Exacerbations needing hospitalisation · people with asthma
Subcutaneous omalizumab + steroid probably leads to lower exacerbations requiring hospitalisation 28 weeks compared with placebo + steroid (steroid reduction) (moderate certainty).
1 finding from 1 review
Intervention not reported
Clinical failure—primary outcome (by intention‐to‐treat analysis) · children with chronic cough of unknown origin lasting longer than 4 weeks
The intervention probably leads to lower clinical failure—primary outcome (by intention‐to‐treat analysis) (moderate certainty).
1 finding from 1 review
Intervention not reported
PC‐QOL mean score at 6 weeks PC‐QOL is a 27‐item questionnaire. Each question has a 7‐point score ranging from 1 (worst quality of life) to 7 (best quality of life). Scores for each item were added and the average taken · children with chronic cough of unknown origin lasting longer than 4 weeks
The intervention probably leads to higher PC‐QOL mean score at 6 weeks PC‐QOL is a 27‐item questionnaire. Each… (moderate certainty).
1 finding from 1 review
Intervention not reported
Duration of cough post randomisation · children with chronic cough of unknown origin lasting longer than 4 weeks
The intervention showed no clear difference in duration of cough post randomisation (moderate certainty).
1 finding from 1 review
Intervention not reported
Proportion of adverse events experienced · children with chronic cough of unknown origin lasting longer than 4 weeks
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Intervention not reported
Proportions of participants experiencing adverse events or complications · children with chronic cough of unknown origin lasting longer than 4 weeks
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Intervention not reported
Average FEV1 % predicted value · adults and children with asthma
1 finding from 1 review
Intervention not reported
Average FVC value · adults and children with asthma
The intervention showed no clear difference in average FVC value (low certainty).
1 finding from 1 review
Intervention not reported
Quality of life: Marks Asthma Quality of Life Questionnaire · adults and children with asthma
1 finding from 1 review
Intervention not reported
Asthma symptoms · adults and children with asthma
The intervention showed no clear difference in asthma symptoms (low certainty).
1 finding from 1 review
Intervention not reported
Asthma control · adults and children with asthma
The intervention may leads to higher asthma control (low certainty).
1 finding from 1 review
Intervention not reported
Beta agonist use; puffs/d · adults and children with asthma
1 finding from 1 review
Intervention not reported
Asthma distress; Asthma Bother Profile · adults and children with asthma
1 finding from 1 review
Change in peak work capacity · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Exercise capacity: percentage change constant work rate endurance time Constant work rate cycle endurance test · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Exercise capacity · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Health‐related quality of life Change in total score of St George Respiratory Questionnaire · patients with chronic obstructive pulmonary disease
1 finding from 1 review